2026 Global: Cancer Monocolonal Antibodies-Competitive Review (2032) report
Description
The 2026 Global: Cancer Monocolonal Antibodies-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cancer monocolonal antibodies by geography and historical trend. The scope of the report extends to sizing of the cancer monocolonal antibodies market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
F. Hoffmann-La Roche Ltd leads the monoclonal antibody therapeutics market in cancer, with a robust oncology portfolio featuring drugs like Tecentriq and Perjeta that target hematological malignancies and solid tumors. Employing advanced recombinant DNA technologies and innovative bispecific formats, Roche drives therapeutic progress through adaptive clinical strategies and heavy R&D investment in personalized medicine. AbbVie Inc. bolsters its position with humanized antibodies addressing oncology alongside immunology, maintaining pipeline depth despite biosimilar challenges to Humira, while focusing on immunology-driven revenues exceeding $56 billion in FY24-25. Merck & Co., Inc. excels in oncology immunotherapies like Keytruda, generating $64.2 billion in revenue through molecular targeting and global distribution, enhanced by strategic acquisitions in 2025 to expand its cancer portfolio.
Bristol-Myers Squibb Company advances cancer treatment via combination therapies and novel antibody formats, leveraging cross-disciplinary partnerships for immune-oncology breakthroughs in complex tumors. Johnson & Johnson, with $88.8 billion in broad therapeutics revenue, diversifies across oncology and immunology monoclonal antibodies, ensuring market stability without reliance on single blockbusters. Amgen Inc. pioneers targeted antibody engineering for oncology and chronic diseases, supported by agile biomanufacturing and supply chain investments amid regulatory shifts. Novartis AG contributes significantly with $50.3 billion in revenues from immunology and oncology monoclonal antibodies, balancing its portfolio through global R&D and 2025 expansions.
Pfizer Inc. maintains a strong oncology presence within its $63.6 billion portfolio, utilizing hybridoma platforms and partnerships for infectious diseases and tumors, navigating post-COVID dynamics. AstraZeneca PLC, generating $54.1 billion, leads in oncology with Tagrisso and Imfinzi, plus respiratory biologics, emphasizing agility in next-generation antibodies and regional approvals. Sanofi S.A., with $44.3 billion in sales, targets rare cancers and autoimmune conditions using recombinant technologies and flexible manufacturing, securing its role through patient-centric global strategies into 2030.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cancer monocolonal antibodies by geography and historical trend. The scope of the report extends to sizing of the cancer monocolonal antibodies market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
F. Hoffmann-La Roche Ltd leads the monoclonal antibody therapeutics market in cancer, with a robust oncology portfolio featuring drugs like Tecentriq and Perjeta that target hematological malignancies and solid tumors. Employing advanced recombinant DNA technologies and innovative bispecific formats, Roche drives therapeutic progress through adaptive clinical strategies and heavy R&D investment in personalized medicine. AbbVie Inc. bolsters its position with humanized antibodies addressing oncology alongside immunology, maintaining pipeline depth despite biosimilar challenges to Humira, while focusing on immunology-driven revenues exceeding $56 billion in FY24-25. Merck & Co., Inc. excels in oncology immunotherapies like Keytruda, generating $64.2 billion in revenue through molecular targeting and global distribution, enhanced by strategic acquisitions in 2025 to expand its cancer portfolio.
Bristol-Myers Squibb Company advances cancer treatment via combination therapies and novel antibody formats, leveraging cross-disciplinary partnerships for immune-oncology breakthroughs in complex tumors. Johnson & Johnson, with $88.8 billion in broad therapeutics revenue, diversifies across oncology and immunology monoclonal antibodies, ensuring market stability without reliance on single blockbusters. Amgen Inc. pioneers targeted antibody engineering for oncology and chronic diseases, supported by agile biomanufacturing and supply chain investments amid regulatory shifts. Novartis AG contributes significantly with $50.3 billion in revenues from immunology and oncology monoclonal antibodies, balancing its portfolio through global R&D and 2025 expansions.
Pfizer Inc. maintains a strong oncology presence within its $63.6 billion portfolio, utilizing hybridoma platforms and partnerships for infectious diseases and tumors, navigating post-COVID dynamics. AstraZeneca PLC, generating $54.1 billion, leads in oncology with Tagrisso and Imfinzi, plus respiratory biologics, emphasizing agility in next-generation antibodies and regional approvals. Sanofi S.A., with $44.3 billion in sales, targets rare cancers and autoimmune conditions using recombinant technologies and flexible manufacturing, securing its role through patient-centric global strategies into 2030.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
